IBTK and infection: Lastly, among the 39 BTKi‐treated patients, 13 (33.3%) developed an infection of any grade, with a median onset of 24 months (IQR 2–37) after BTKi initiation, which aligns with a real‐world prospective cohort from Italy (30.7%) [16].